Lievre M, Ollagnier M, Faucon G
Arzneimittelforschung. 1979;29(8a):1227-31.
The cerebral vasodilatory effect of 10-methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) was examined by recording the cardiac output of the vertebral artery in the dog. As from a dosage of 25 micrograms/kg nicergoline increases permanently the cardiac output to a normal or nearly normal level which had been decreased by phenylephrine reducing the increased local vascular resistance. The alpha-sympatholytical properties of nicergoline were more precisely proved by reducing the reactive increase in blood pressure after epinephrine and norepinephrine (3 micrograms/kg) by administration of nicergoline in 3 doses (25, 50 and 100 micrograms/kg). The same method was used with phentalamine in dosages of 125, 250 and 500 micrograms/kg. The statistical comparison of the results obtained with both substances shows that the ratio of equiactive doses is about 3:1 in favour of nicergoline.
通过记录犬椎动脉的心输出量，研究了10-甲氧基-1,6-二甲基麦角灵-8β-甲醇-（5-溴烟酸酯）（尼麦角林，喜得镇）的脑血管舒张作用。从25微克/千克的剂量开始，尼麦角林可使心输出量持续增加至正常或接近正常水平，该水平此前因去氧肾上腺素降低局部血管阻力增加而降低。通过给予3种剂量（25、50和100微克/千克）的尼麦角林，降低肾上腺素和去甲肾上腺素（3微克/千克）后血压的反应性升高，更精确地证明了尼麦角林的α-交感神经阻滞特性。以125、250和500微克/千克的剂量使用酚妥拉明采用相同方法。对两种药物所得结果进行统计学比较表明，等效活性剂量之比约为3:1，尼麦角林更具优势。
